for people ages 18 years and up (full criteria)
at UC Irvine
study started
estimated completion
Principal Investigator
Ritesh Parajuli (uci)



This trial studies SGN-LIV1A with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs. A side effect is anything the drugs do besides treating cancer. Pembrolizumab is a drug that can be used to treat triple-negative breast cancer. The trial will also find out if the drugs work to treat this type of cancer. Participants in this study have metastatic breast cancer. This means the cancer has spread to other parts of the body.

Official Title

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer


The primary goal of this study is to evaluate the combination of SGN-LIV1A, which targets LIV-1- expressing tumor cells, with the checkpoint inhibitor pembrolizumab for patients with unresectable locally-advanced or metastatic triple-negative breast cancer. These two drugs act through distinct and possibly complementary modes of action.

This is a single-arm, open-label, multicenter trial. Patients given SGN-LIV1A and pembrolizumab during dose escalation will be monitored for frequency of dose-limiting toxicities to determine a recommended doses for expansion cohorts. In addition to safety measures, objective response rate, progression-free survival, overall survival, and other efficacy outcomes will be assessed.


Breast Neoplasms Breast cancer Breast carcinoma Triple negative breast cancer Locally-advanced breast cancer Metastatic breast cancer Tumors, breast Breast tumors pembrolizumab LIV-1 protein, human Ladiratuzumab vedotin hLIV22-vcMMAE Triple Negative Breast Neoplasms SGN-LIV1A SGN-LIV1A plus pembrolizumab


You can join if…

Open to people ages 18 years and up

  • Metastatic or locally-advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)
  • Have not previously received cytotoxic therapy for the treatment of unresectable locally-advanced breast cancer or metastatic breast cancer
  • At least 6 months since prior treatment with curative intent and recurrence
  • At least 1 tumor 10mm in diameter or greater OR lymph node of at least 15 mm in short axis
  • ECOG performance status of 0 or 1
  • Able to provide biopsy tissue for biomarker analysis
  • Meet baseline laboratory data criteria
  • Not pregnant. Must agree not to become pregnant until at least 6 months after ceasing study treatment

You CAN'T join if...

  • Prior immune-oncology therapy
  • Pre-existing neuropathy of at least Grade 2
  • History of carcinomatous meningitis or active central nervous system (CNS) metastases. Patients are eligible if CNS metastases are adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 4 weeks prior to enrollment. Patients must be off corticosteroids.
  • Received prior radiotherapy within 2 weeks of start of study treatment or have not adequately recovered from prior radiotherapy
  • Active autoimmune disease requiring systemic treatment within the past 2 years
  • History of interstitial lung disease
  • Current pneumonitis or history of pneumonitis requiring steroids


  • Chao Family Comprehensive Cancer Center University of California Irvine accepting new patients
    Orange California 92868 United States
  • University of California Irvine - Newport accepting new patients
    Orange California 92868 United States
  • Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute accepting new patients
    Los Angeles California 90048 United States

Lead Scientist at UC Cancer

  • Ritesh Parajuli (uci)
    Assistant Health Sciences Professor, Medicine. Authored (or co-authored) 5 research publications.


accepting new patients
Start Date
Completion Date
Seattle Genetics, Inc.
Phase 1/2
Study Type
Last Updated